Breast Imaging

Should You Order Screening Imaging for a Male Under 25 with Breast Cancer Risk Factors?

·
Should You Order Screening Imaging for a Male Under 25 with Breast Cancer Risk Factors?

A 22-year-old male student comes to your clinic for a routine physical. During the visit, he mentions that his paternal aunt was diagnosed with breast cancer in her 40s, and he’s read online about genetic risks. He is asymptomatic but asks if he should get a “baseline mammogram” for screening, given his family history. You are now faced with the decision of whether to order imaging for breast cancer screening in a very young male patient. This article details the American College of Radiology (ACR) Appropriateness Criteria for this specific scenario, explaining the rationale for why imaging is not the recommended path. For an adult male younger than 25, regardless of risk factors, all imaging modalities for breast cancer screening are considered Usually not appropriate.

Who Fits This Clinical Scenario?

This guidance applies to a specific and narrowly defined patient population: asymptomatic adult males who are younger than 25 years of age. The key inclusion criteria are:

  • Patient Sex: Male
  • Patient Age: Under 25 years
  • Indication: Screening for breast cancer
  • Symptoms: Asymptomatic (no palpable lump, nipple discharge, skin changes, or focal pain)
  • Risk Level: Any, from average to high-risk (e.g., known genetic mutation like BRCA1/2, strong family history)

It is critical to distinguish this screening scenario from a diagnostic workup. This guidance does not apply to a young male patient who presents with a palpable breast lump, skin dimpling, or bloody nipple discharge. Such a presentation requires a diagnostic evaluation, which falls under a different set of ACR guidelines (e.g., Palpable Breast Mass). Similarly, this article does not cover older men, for whom screening recommendations may differ based on their specific risk profile, particularly those with a higher-than-average risk.

What Diagnoses Are You Working Up in This Scenario?

In a screening context for a male under 25, the primary concern being evaluated is the potential for subclinical male breast cancer. However, the clinical reality is that the pre-test probability of this diagnosis is exceedingly low, which heavily influences the screening recommendation. The “differential” in this asymptomatic patient is more a consideration of baseline anatomy and common benign conditions that can mimic or be mistaken for pathology on imaging.

Male Breast Cancer: While this is the target of screening, it is exceptionally rare in this age group. The incidence of breast cancer in men is about 100 times less common than in women, and the median age of diagnosis is around 70. For men under 25, the occurrence is so infrequent that it is considered a sporadic event, making population-based or even high-risk screening ineffective.

Gynecomastia: This is the most common cause of breast tissue enlargement in males and is a benign proliferation of glandular tissue. It is particularly common during puberty and in young adulthood. On imaging, gynecomastia can sometimes appear complex, potentially leading to false-positive findings that trigger unnecessary biopsies and patient anxiety. Since it is a benign and often self-resolving condition, imaging it in an asymptomatic patient is not indicated.

Pseudogynecomastia: This is another common, benign condition characterized by fat deposition in the breast area without glandular proliferation. It is related to body habitus and is not a risk factor for cancer. It cannot be distinguished from true gynecomastia by physical exam alone, but like gynecomastia, it does not warrant screening imaging.

Why Is Imaging Usually Not Appropriate for This Presentation?

The ACR panel rates all imaging modalities for breast cancer screening in males under 25 as “Usually not appropriate.” This recommendation is grounded in the fundamental principle of balancing the potential benefits of a test against its potential harms. In this specific clinical scenario, the harms of screening substantially outweigh the benefits.

The core rationale is the extremely low incidence of breast cancer in this demographic. The likelihood of detecting a clinically meaningful cancer in an asymptomatic male under 25 is vanishingly small. Attempting to screen for such a rare event leads to a high probability of false-positive results. Benign conditions like gynecomastia are very common and can create imaging findings that require further investigation, including biopsies, causing significant patient anxiety and healthcare costs for no clinical benefit.

Let’s review the specific modalities and why they are not recommended:

  • Mammography Screening and Digital Breast Tomosynthesis (DBT): Both are rated Usually not appropriate. While mammography is the standard for female breast cancer screening, its use in young men for this purpose is unsupported. It involves ionizing radiation (adult RRL ☢☢ 0.1-1 mSv), and the potential for false positives from dense glandular tissue or gynecomastia is high. The radiation exposure, though small, is not justified given the near-zero chance of detecting cancer.
  • Breast Ultrasound (US): This modality is also rated Usually not appropriate for screening. Although it avoids ionizing radiation (adult RRL O 0 mSv), its use as a primary screening tool is not validated in any male population, let alone young men. Its high sensitivity for detecting any tissue variation means it would frequently identify benign findings like cysts or gynecomastia, leading to a cascade of unnecessary follow-up tests.
  • Breast MRI (with or without contrast): All forms of breast MRI are rated Usually not appropriate for screening in this group. While MRI is a highly sensitive test used for screening in high-risk women, its specificity can be low. The high cost, need for IV contrast in most protocols, and potential for identifying benign enhancing areas make it an unsuitable screening tool for a condition this rare.

What’s Next? Downstream Workflow

Given that imaging is not recommended, the appropriate downstream workflow focuses on clinical management, patient education, and risk stratification rather than radiological studies.

If the patient is asymptomatic but high-risk: The most appropriate next step is not imaging, but a formal risk assessment and consideration for genetic counseling. This is particularly important for patients with a known BRCA1/2 mutation in the family or a significant history of breast, ovarian, pancreatic, or prostate cancer. Genetic counseling can clarify the patient’s personal risk and provide guidance on future management, which may include surveillance starting at an older age.

If the patient is asymptomatic and average-risk: The workflow is reassurance and education. Teach the patient breast self-awareness, advising him to seek medical attention if he notices any new changes, such as a firm lump, skin puckering, or nipple changes. Regular clinical breast exams as part of annual physicals are also reasonable.

If the patient develops a symptom (e.g., a palpable lump): The clinical scenario changes immediately from screening to diagnostic. At this point, the patient no longer fits this guideline. A focused diagnostic workup, typically starting with a targeted breast ultrasound, becomes appropriate. Depending on the ultrasound findings, a diagnostic mammogram and subsequent biopsy may be warranted.

Pitfalls to Avoid (and When to Get Help)

Navigating this scenario requires careful communication and adherence to evidence-based guidelines. Common pitfalls include:

  • Ordering imaging for patient reassurance: While well-intentioned, ordering a “just in case” ultrasound or mammogram goes against guidelines and risks initiating a harmful cascade of unnecessary tests and anxiety for a near-zero benefit.
  • Confusing screening with a diagnostic workup: If a patient has a physical finding, do not apply this screening guideline. A palpable mass requires a diagnostic imaging evaluation, starting with ultrasound.
  • Underestimating the value of genetic counseling: For a young man with a truly significant family history, the most valuable intervention is a referral for genetic counseling to quantify his risk, not premature imaging.

If a clinical breast exam reveals a suspicious, firm, fixed, or eccentric mass, you should immediately escalate the workup. This is no longer a screening situation; proceed directly to ordering diagnostic imaging and consider a referral to a breast specialist or surgeon.

Related ACR Topics and Tools

For a comprehensive overview of imaging recommendations across all male breast cancer screening scenarios, including for older and higher-risk men where imaging may be considered, please consult our parent guide. For additional tools to help with clinical decision-making, see the resources below.

Frequently Asked Questions

What if my patient under 25 has a known BRCA2 mutation? Should he still not get screening?

Even with a known high-risk genetic mutation like BRCA2, the American College of Radiology (ACR) guidelines still rate screening imaging as ‘Usually not appropriate’ for males under 25. The rationale is that the absolute risk of developing breast cancer at such a young age remains extremely low, and the risks of false positives from screening outweigh the potential benefits. The standard recommendation is to begin clinical surveillance and consider imaging screening at an older age, typically starting around 35, in consultation with a high-risk specialist.

Isn’t an ultrasound harmless? Why not order one just for reassurance?

While breast ultrasound does not use ionizing radiation, it is not considered ‘harmless’ in a screening context. Because it is highly sensitive, it can detect many benign findings, such as simple gynecomastia or small cysts, which are very common in young men. These findings can be labeled ‘indeterminate,’ leading to a cascade of follow-up imaging, anxiety, and potentially unnecessary biopsies. For a condition as rare as breast cancer in this age group, the high false-positive rate makes screening US more likely to cause harm than good.

What is the difference between screening and a diagnostic workup for a male breast concern?

Screening is the process of looking for a disease, like cancer, in an asymptomatic person who has no signs of the disease. This article covers screening. A diagnostic workup, on the other hand, is performed when a patient has a specific sign or symptom, such as a palpable lump, nipple discharge, or skin changes. If a young man has a palpable lump, he needs a diagnostic evaluation (typically starting with ultrasound), not a screening study. The recommendations for diagnostic imaging are completely different.

My patient has gynecomastia. Does this increase his risk for breast cancer?

No, typical gynecomastia (benign proliferation of glandular tissue) is not considered a risk factor for developing male breast cancer. While some conditions that cause gynecomastia, such as Klinefelter syndrome, are associated with an increased risk of breast cancer, the gynecomastia itself is not the cause. For most young men, gynecomastia is a common, benign, and often temporary condition that does not require imaging or increase their long-term cancer risk.

At what age should a high-risk male (e.g., with a BRCA mutation) start breast cancer screening?

Recommendations can vary, but many guidelines, including those from the National Comprehensive Cancer Network (NCCN), suggest that men with a BRCA mutation begin annual clinical breast exams starting at age 35. The NCCN also states that an annual screening mammogram may be considered for BRCA carriers starting at age 40, after discussing the risks and benefits. The decision should be made in consultation with a genetic counselor or a high-risk breast clinic.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026